Key Drivers
- Strong Liquidity
- Rising Losses
- Negative Cash Flow
AIAI Summary
SUPN is now primarily a stock-for-stock Indivior merger-arbitrage and integration-execution play—not a standalone CNS growth story—so investors should focus on deal completion, Indivior share performance, and delivery of $125M in synergies while requiring evidence that SUPN's strong revenue growth converts back to positive cash flow.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Rising Losses
- •Negative Cash Flow
SUPN has strong liquidity and high gross margins, but worsening losses, negative cash flow, and intangible-heavy assets make the current 2.59x book and 3.22x sales valuation difficult to justify.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Support holding
- •Weak rebound
SUPN remains in a short-term downtrend, with support at $41.28–$41.38 and a sustained move above $43.28 needed to signal stabilization.
Late-August rally to $49.03 was followed by a sharp decline
Sentiment & News
Key News Insights:
- •Fairness investigation
- •Institutional buying
- •CNS expansion
Indivior's proposed Supernus acquisition offers strategic CNS expansion and strong institutional interest, but fairness scrutiny and closing uncertainty remain key risks.
The deal could support Supernus shares, though governance concerns may temper upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings